Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

Background: Long-term data on inflammatory bowel disease (IBD) patients switched from originator to biosimilar infliximab SB2 are lacking. The aim of the conducted study was to investigate the effectiveness, immunogenicity and safety of a large prospectively followed-up IBD patient cohort that was e...

Full description

Bibliographic Details
Main Authors: Sarah Fischer, Sarah Cohnen, Entcho Klenske, Heike Schmitt, Francesco Vitali, Simon Hirschmann, Andreas Ramming, Sebastian Zundler, Timo Rath, Sabine Krebs, Frank Dörje, Wolfgang Uter, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya
Format: Article
Language:English
Published: SAGE Publishing 2021-01-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284820982802

Internet

https://doi.org/10.1177/1756284820982802

Similar Items